stride semaglutide study and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial Evaluating the Cardiovascular Benefits of – Semaglutide Boosts PAD Outcomes in

The oral tirzepatide formulation is not yet widely available, though some compounding pharmacies offer it

BMI-Based Eligibility for Weight Loss Most healthcare providers follow criteria similar to those established for FDA-approved weight loss medications: BMI of 30 or higher (obesity): You may qualify for Ozempic off-label for weight loss if your BMI indicates obesity, even without weight-related health conditions

In the UK, both options are available on NHS prescription for eligible patients with type 2 diabetes, subject to local formulary guidance and NICE recommendations (TA667 and NG28)

Off-label prescribing is a common and legal medical practice when the benefits outweigh the risks and when supported by clinical evidence